Cogent Biosciences, Inc. (COGT)

NASDAQ: COGT · IEX Real-Time Price · USD
8.21
-0.06 (-0.73%)
Dec 5, 2023, 9:49 AM EST - Market open
-0.73%
Market Cap 712.25M
Revenue (ttm) n/a
Net Income (ttm) -177.66M
Shares Out 86.12M
EPS (ttm) -2.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 18,070
Open 8.19
Previous Close 8.27
Day's Range 8.13 - 8.27
52-Week Range 6.43 - 15.68
Beta -0.20
Analysts Strong Buy
Price Target 22.83 (+178.08%)
Earnings Date Nov 2, 2023

About COGT

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target exon 17 mutations found within the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercializat... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 29, 2018
Employees 138
Stock Exchange NASDAQ
Ticker Symbol COGT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for COGT stock is "Strong Buy." The 12-month stock price forecast is $22.83, which is an increase of 178.08% from the latest price.

Price Target
$22.83
(178.08% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium

WALTHAM, Mass. and BOULDER, Colo., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...

6 days ago - GlobeNewsWire

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results

SUMMIT and APEX clinical presentations planned for 2023 ASH Annual Meeting; SUMMIT NonAdvSMdata selected for oral presentation

4 weeks ago - GlobeNewsWire

Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

– Novel selective and reversible FGFR2 inhibitor exhibits strong potency across key primary and resistance driver mutations with potential advantages over covalent approaches –

7 weeks ago - GlobeNewsWire

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results

Initial clinical results from Phase 2 SUMMIT trial in NonAdvSM along with updated data from Phase 2 APEX trial in AdvSM on track for 2H 2023

4 months ago - GlobeNewsWire

3 Lost Formula Stocks to Consider for the 2nd Half of 2023

Having ended 2022 on a low note, U.S. market indexes have overall shown stronger performances so far in 2023.

Other symbols: CRCIRWD
5 months ago - GuruFocus

Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock

WALTHAM, Mass. and BOULDER, Colo., June 09, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...

6 months ago - GlobeNewsWire

Cogent Biosciences Announces Participation in the Jefferies Healthcare Conference

WALTHAM, Mass. and BOULDER, Colo., June 07, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...

6 months ago - GlobeNewsWire

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

WALTHAM, Mass. and BOULDER, Colo., June 06, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...

6 months ago - GlobeNewsWire

Cogent Biosciences Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass. and BOULDER, Colo., June 06, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically define...

6 months ago - GlobeNewsWire

Cogent Biosciences Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST)

-  Data presented at ASCO annual meeting demonstrate 55% Disease Control Rate (DCR) in heavily pre-treated GIST patients, including 100% DCR and 17% overall response rate (ORR) in efficacy evaluable 2...

6 months ago - GlobeNewsWire

Cogent Biosciences Reports Recent Business Highlights and First Quarter 2023 Financial Results

Lead-in data from Phase 3 PEAK trial to be presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

7 months ago - GlobeNewsWire

Cogent Biosciences Announces Participation at Upcoming Investor Conferences

WALTHAM, Mass. and BOULDER, Colo., April 12, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically define...

8 months ago - GlobeNewsWire

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results

WALTHAM, Mass. and BOULDER, Colo., March 14, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically define...

9 months ago - GlobeNewsWire

Cogent Biosciences Announces Planned 2023 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Cancer Therapeutics

WALTHAM, Mass. and BOULDER, Colo., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined...

11 months ago - GlobeNewsWire

Cogent Biosciences Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass. and BOULDER, Colo., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...

11 months ago - GlobeNewsWire

Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

-   89% ORR in TKI-therapy naïve patients; 73% ORR in all evaluable patients with 27-week median follow-up

1 year ago - GlobeNewsWire

Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis

WALTHAM, Mass. and BOULDER, Colo., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined...

1 year ago - GlobeNewsWire

Cogent Biosciences Appoints Rachael Easton, MD, Ph.D., VP, Head of Clinical Development

WALTHAM, Mass. and BOULDER, Colo., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined...

1 year ago - GlobeNewsWire

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results

Phase 3 PEAK trial initiated comparing bezuclastinib + sunitinib vs. sunitinib alone in second line gastrointestinal stromal tumor (GIST) patients; initial safety and pharmacokinetic data from lead-in...

1 year ago - GlobeNewsWire

Cogent Biosciences Announces Bezuclastinib Presentations at the 64th Annual American Society of Hematology (ASH) Meeting

Company to Host Virtual Investor Event on Monday, December 12 Company to Host Virtual Investor Event on Monday, December 12

1 year ago - GlobeNewsWire

Cogent Biosciences to Showcase Precision Therapy Pipeline at the EORTC-NCI-AACR Annual Meeting

WALTHAM, Mass. and BOULDER, Colo., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...

1 year ago - GlobeNewsWire

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2022 Financial Results

On-track to present additional data from Phase 2 APEX trial by the end of 2022

1 year ago - GlobeNewsWire

Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

CAMBRIDGE, Mass. and BOULDER, Colo., June 16, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically define...

1 year ago - GlobeNewsWire